Markees T G, Phillips N E, Noelle R J, Shultz L D, Mordes J P, Greiner D L, Rossini A A
Diabetes Division, University of Massachusetts Medical School, Biotech 2, Worcester 01605, USA.
Transplantation. 1997 Jul 27;64(2):329-35. doi: 10.1097/00007890-199707270-00026.
Combined treatment with antibody against CD40 ligand and one transfusion of donor splenocytes prolonged survival of fully mismatched BALB/c skin allografts on C57BL/6 recipients, with approximately 20% of grafts surviving > 100 days. In vitro alloresponsiveness in treated animals was reduced in the immediate post-transplantation period, but by day 100 was increased despite the presence of a successful allograft. The presence of alloreactivity on day 100 was confirmed in vivo by adoptive transfer, which suggests that our protocol had induced either a state of "split tolerance" or "graft accommodation." Mice with skin grafts that had survived for > or = 100 days revealed no evidence of lymphoid chimerism. Treatment with donor splenocytes and antibody against CD40 ligand permits long-term survival of highly antigenic donor skin allografts despite the presence of functionally intact alloreactive lymphocytes.
抗CD40配体抗体与一次供体脾细胞输注联合治疗可延长C57BL/6受体上完全不匹配的BALB/c皮肤同种异体移植物的存活时间,约20%的移植物存活超过100天。在移植后的即刻,经治疗动物的体外同种异体反应性降低,但到第100天时,尽管存在成功的同种异体移植物,其反应性却增加了。通过过继转移在体内证实了第100天时存在同种异体反应性,这表明我们的方案诱导了“分离耐受”或“移植物适应”状态。皮肤移植物存活≥100天的小鼠未显示淋巴嵌合的证据。尽管存在功能完整的同种异体反应性淋巴细胞,但用供体脾细胞和抗CD40配体抗体治疗可使高抗原性供体皮肤同种异体移植物长期存活。